胰腺癌组织MMP-2表达及其意义的探讨  

Research on expression of MMP-2 in patients with pancreatic cancer

作　　者：李杰[1] 童春帆[2] 李强[2] 

机构地区：[1]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院儿童肿瘤科,天津300060 [2]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院肝胆肿瘤科,天津300060

出　　处：《中华肿瘤防治杂志》2010年第21期1761-1763,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨胰腺癌基质金属蛋白酶2(MMP-2)表达及与胰腺癌临床病理因素的关系。方法:应用免疫组化方法检测58例胰腺癌和10例胰腺良性病变标本MMP-2表达情况,单因素分析MMP-2与胰腺癌患者预后的关系。结果:高中分化腺癌阳性率(57.1%)低于低分化腺癌阳性率(87.5%),P<0.05。从TNMⅠ期到Ⅲ期,MMP-2阳性率逐渐升高,分别为14.3%(1/7),56.7%(17/30),95.2%(20/21),P<0.05。但性别、年龄、肿瘤部位和肿瘤大小差异无统计学意义,P>0.05。胰腺良性病变中MMP-2的阳性率为40.0%,胰腺癌中MMP-2阳性率为65.5%,胰腺癌引流淋巴结中MMP-2阳性率为87.9%,3组间表达差异有统计学意义(P<0.05),MMP-2阳性胰腺癌患者生存率较阴性组低,差异具有统计学意义。结论:MMP-2与临床胰腺癌患者肿瘤的侵袭转移及预后相关,检测MMP-2表达情况可以作为临床胰腺癌预后判断的一个指标。OBJECTIVE：To investigate the expression of MMP-2 in pancreatic cancer and tumor draining lymph nodes（TDLNs）,and seek the relationship between the expression of MMP-2 and the prognosis of pancreatic cancer.METHODS：Fifty-eight cases of pancreatic cancer and 10 cases of pancreatic benign diseases were collected.Immunohistochemistry was used to detect the expression of MMP-2 in pancreatic cancer,TDLNs and benign diseases.RESULTS：The expression of MMP-2 in high and medion differentiation（57.1%） was lower than that in low differentiation（87.5%,P0.05）.Immunohistochemistry results showed that the positive rate of MMP-2 in TDLNs（87.9%） was higher than that in pancreatic cancer（65.5%,P0.05）,and that in pancreatic cancer was higher than that in benign diseases（40.0%,P0.05）.The expression of MMP-2 protein in pancreatic cancer was associated with the clinical stage（14.3%,56.7% and 95.2% from TNM Ⅰ to TNM Ⅲ,P0.05）,but not with the pathological type.There was a statistical difference in survival time between MMP-2 positive cases and negative cases（P0.05）.CONCLUSIONS：The high expression of MMP-2 is increased in pancreatic cancer and TDLNs,which suggests that MMP-2 may involved in pancreatic cancer metastasis.MMP-2 may be regarded as an important marker in prognosis judgment.

关 键 词：胰腺肿瘤 基质金属蛋白酶2 免疫组化 生存率 

分 类 号：R735.9[医药卫生—肿瘤]